Professor, Internal Medicine, Wayne State University School of Medicine
Hematology
Dr. Lawrence E. Flaherty, MD
|
|
Give Review
Doctor Lawrence E. Flaherty, MD works in the field of Hematology. He studied medicine at Saint Louis University School of Medicine. Saint Louis University School of Medicine has a rank of 67 in research and a 57 in primary care He received awards:"Super Doctor" and "Top MD". Lawrence E. Flaherty, MD is also published. He has 96 publications published. The lastest publication: "Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.'
Publications
- SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer.
- New options for the adjuvant treatment of cutaneous Melanoma?
- Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival.
- Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine DTIC, Plus Interleukin-2 and Interfero...
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic Melanoma: SWOG 0933.
- Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma.
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438).
- SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast Cancer.
- Targeted therapies: Improved outcomes for patients with metastatic Melanoma.
- A phase 2 trial of complete resection for stage IV Melanoma: Results of Southwest Oncology Group Clinical Trial S9430.
- A phase II trial of imatinib mesylate in merkel cell Carcinoma (neuroendocrine Carcinoma of the skin): A Southwest Oncology Group study (S0331).
- Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic Malignant melanoma: Southwest Oncology Group S0508.
- Evaluation of interferon alpha-2B and thalidomide in patients with disseminated Malignant melanoma, phase 2, SWOG 0026.
- Phase II trial of interferon and thalidomide in metastatic renal cell Carcinoma.
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell Carcinoma.
- Biochemotherapy of Melanoma.
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative Melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the South...
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic Melanoma in the United States.
- The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors.
- The math of making mutant mice.
- Hot topics in behavioral and neural genetics.
- Localization of two new X-linked quantitative trait loci controlling corpus callosum size in the mouse.
- Inbred strain variation in contextual and cued fear conditioning behavior.
- Serologic cross-reactivity between Class I MHC molecules and an H-2-linked differentiation antigen as detected by monoclonal antibodies.
- Identification of genes within the Krd deletion on mouse chromosome 19.
- Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
- Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim Analysis of data from a phase III, multi-institutional trial.
- Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic Melanoma.
- Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final Analysis of data from a phase III, randomized, double-blind, multicente...
- Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic Melanoma: a Southwest Oncology Group trial.
- Phase II chemoprevention trial of oral fenretinide in patients at risk for adenoCarcinoma of the prostate.
- Scintigraphic findings in patients with shoulder pain caused by interleukin-2.
- A phase III randomized, double-blind multiinstitutional trial of vaccinia Melanoma oncolysate-active specific immunotherapy for patients with stage II Melanoma.
- Treatment of metastatic Malignant melanoma.
- A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast Cancer.
- Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with Cancer.
- Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in Melanoma patients.
- SWOG 8825: melphalan GM-CSF: a phase I study.
- Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue Sarcoma.
- Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.
- Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
- Biochemotherapy for Melanoma.
- Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic Malignant melanoma: results of two phase II cytokine working group tri...
- Use and abuse of statistics in evidence-based medicine.
- Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
- Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous Melanoma: a Southwest Oncology Group study.
- Temozolomide and whole Brain irradiation in melanoma metastatic to the Brain: a phase II trial of the Cytokine Working Group.
- Oral etoposide in the treatment of hormone-refractory prostate Cancer.
- A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic Malignant melanoma: a phase 2 consortium study.
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenoCarcinoma of the prostate.
- 5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung Cancer.
- Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
- Chronic oral administration of CI-994: a phase 1 study.
- Reversible cardiomyopathy after high-dose interleukin-2 therapy.
- Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced Melanoma.
- Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell Carcinoma.
- Factors associated with breast Cancer clinical trials participation and enrollment at a large academic medical center.
- A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast Cancer.
- Sequential dacarbazine/cisplatin and interleukin-2 in metastatic Melanoma: immunological effects of therapy.
- Adjuvant high-dose interferon revisited.
- Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with Cancer: attempt to induce autologous graft-versus-host reaction to e...
- Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic Melanoma.
- Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate Carcinoma.
- Treatment of Malignant melanoma with interleukin-2.
- A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate Cancer.
- Phase II trial of CI-980 in patients with disseminated Malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
- Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk Melanoma: pathologic corollary of Eastern Cooperat...
- Phase II trial of recombinant human interleukin-4 in patients with disseminated Malignant melanoma: a Southwest Oncology Group study.
- High- and low-dose interferon alfa-2b in high-risk melanoma: first Analysis of intergroup trial E1690/S9111/C9190.
- A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV Melanoma: a Southwest Oncology Group study.
- Dacarbazine and outpatient interleukin-2 in treatment of metastatic Malignant melanoma: phase II Southwest Oncology Group trial.
- Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced Melanoma: a Southwest Oncology Group study.
- Evaluation of merbarone (NSC 336628) in disseminated Malignant melanoma. A Southwest Oncology Group study.
- A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenoCarcinoma of the prostate.
- Effect of calcium replacement on the hemodynamic changes associated with high dose interleukin-2 therapy.
- A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with Cancer.
- A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell Cancer.
- Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in meta...
- The addition of tamoxifen to dacarbazine and cisplatin in metastatic Malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
- A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic Malignant melanoma.
- A phase II trial of piroxantrone in disseminated Malignant melanoma. A Southwest Oncology Group study.
- A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic Malignant melanoma.
- Phase II study of deoxydoxorubicin in previously untreated metastatic breast Cancer.
- Gender and other survival predictors in patients with metastatic Melanoma on Southwest Oncology Group trials.
- Metastatic melanoma from intraocular primary Tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.
- Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial Carcinoma.
- Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell Carcinoma.
- Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell Carcinoma.
- A phase II trial of pyrazine diazohydroxide in patients with disseminated Malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative Melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
- ACCO: ASCO core curriculum outline.
- Phase II trial of pegylated interferon and thalidomide in Malignant metastatic melanoma.
- Risk assessment in localized primary cutaneous Melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression predictio...
- Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and d...
- Adjuvant therapy of Melanoma: is pegylated interferon alfa-2b what we''ve been waiting for?
Schools
Saint Louis University School Of Medicine
Med College Of Wisconsin
University Of Pennsylvania
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
- Top MD
Education
-
University of Pennsylvania Health System -
Medical College of Wisconsin Affiliated Hospitals -
Saint Louis University School of Medicine
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1124065610 | |
| NPPES Provider LastName | FLAHERTY | |
| NPPES Provider FirstName | LAWRENCE | |
| NPPES Provider ZIPCode | 48201 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 558.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 3.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124065610 |
| Last Name Of The Provider | FLAHERTY |
| First Name Of The Provider | LAWRENCE |
| View All |
Similar Doctors
|
|
Dr. Michael S. Simon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Fontana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abhinav Deol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leilei Chen, MD |
|
|
Dr. Leslie J. Bricker, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Shatha Y. Farhan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmed O. Kaseb, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vijayalakshmi Donthireddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravneet Thind, MD |
|
|
Dr. Jyotinder N. Punia, MD |
|
|
Dr. Richard M. Zuniga, MD |
|
|
Dr. Kinda Hayek, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Mouhammad Z. Eldean |
|
|
Dr. Jatin Rana, MD |
|
|
Rashmi Kanagal Shamanna, MB |
|
|
George Yaghmour |